Study #2020-0534
A Phase Ib /II Study of Safety, Tolerability and Efficacy of APG- 2575 Alone or in Combination with Other Therapeutic Agents in Patients with Waldenström Macroglobulinemia (WM)
MD Anderson Study Status
Not Accepting
Treatment Agent
APG2575 400 mg, APG2575 600 mg, APG2575 800 mg
Description
Phase Ib/II study of safety, tolerability, efficacy and PK of APG-2575 as a single agent or in combination with other therapeutic agents including ibrutinib or rituximab.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Waldenstrom Macroglobulinemia
Study phase:
Phase I
Physician name:
Sheeba Thomas
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-317-6206
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.